UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of incorpor ...

® Corporate Presentation April 29, 2021 The information in this slide deck is current as of April 29, 2021, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements 2 Legal Notices Any statements in these materials about future expectations, plans and prospects for MacroGenics ("Company"), including ...

MacroGenics, Inc. (NASDAQ:MGNX) Q1 2021 Earnings Conference Call April 29, 2021 4:30 PM ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President & Chief Executive Officer Jim Karrels - Senior Vice President & Chief Financial Officer Conference Call Participants Jonathan Chang - SVB Leerink Peter Lawson - Barclays Jonathan Miller - Evercore ISI Stephen Willey - Stifel Yigal Nochomovitz - Citigroup Bradley Canino - Credit Suisse Etzer Darout - Guggenheim Securities David Lebowitz ...

WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of incorpo ...

® Corporate Presentation February 25, 2021 The information in this slide deck is current as of February 25, 2021, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements 2 Legal Notices Any statements in these materials about future expectations, plans and prospects for MacroGenics ("Company"), incl ...

MacroGenics, Inc. (NASDAQ:MGNX) Q4 2020 Earnings Conference Call February 25, 2020 4:30 PM ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President and Chief Executive Officer Jim Karrels - Senior Vice President and Chief Financial Officer Conference Call Participants Evan Seigerman - Credit Suisse David Ruch - SVB Leerink Bo Chen - Evercore ISI David Lebowitz - Morgan Stanley Mitchell Kapoor - Barclays Operator Good afternoon. We will begin the MacroGenics 2020 Fourth Quarter a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36112 MACROGENICS, INC. (Exact name of registrant) Delaware 06-1591613 (State of organization) (I.R.S. Employer Identification Number ...

® Corporate Presentation December 1, 2020 The information in this slide deck is current as of December 1, 2020, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements 2 Legal Notices Any statements in these materials about future expectations, plans and prospects for MacroGenics ("Company"), includ ...

® Developing Breakthrough Biologics, Life-changing Medicines™ Corporate Presentation November 4, 2020 The information in this slide deck is current as of November 4, 2020, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements 2 Legal Notices Any statements in these materials about future expectati ...

MacroGenics, Inc. (NASDAQ:MGNX) Q3 2020 Earnings Conference Call November 4, 2020 4:30 PM ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President and CEO Jim Karrels - CFO Stephen Eck - CMO Conference Call Participants Yigal Nochomovitz - Citigroup Evan Seigerman - Credit Suisse Jonathan Miller - Evercore Stephen Willey - Stifel Etzer Darout - Guggenheim Securities Peter Lawson - Barclays Yigal Nochomovitz - Citigroup Operator Good afternoon. We will begin the MacroGenics 2020 ...